Structures by: Fabbiani F. P.
Total: 92
Rubrene
C42H28
The Journal of Physical Chemistry C (2014) 118, 25 13476
a=6.6779(5)Å b=7.9256(17)Å c=11.3415(16)Å
α=89.367(17)° β=104.460(7)° γ=96.321(9)°
Rubrene
C42H28
The Journal of Physical Chemistry C (2014) 118, 25 13476
a=7.0883(7)Å b=8.5994(8)Å c=12.0059(11)Å
α=93.486(5)° β=105.642(5)° γ=95.977(5)°
Rubrene
C42H28
The Journal of Physical Chemistry C (2014) 118, 25 13476
a=6.6350(3)Å b=7.7995(16)Å c=11.2182(14)Å
α=88.437(17)° β=104.348(7)° γ=96.316(8)°
Rubrene
C42H28
The Journal of Physical Chemistry C (2014) 118, 25 13476
a=6.8535(4)Å b=8.2642(12)Å c=11.6573(11)Å
α=91.614(11)° β=104.921(5)° γ=96.311(7)°
Rubrene
C42H28
The Journal of Physical Chemistry C (2014) 118, 25 13476
a=6.7392(4)Å b=8.0591(15)Å c=11.4641(14)Å
α=90.271(15)° β=104.627(6)° γ=96.329(8)°
Rubrene
C42H28
The Journal of Physical Chemistry C (2014) 118, 25 13476
a=7.0478(3)Å b=8.5495(13)Å c=11.9485(11)Å
α=93.201(11)° β=105.501(5)° γ=96.079(6)°
Rubrene
C42H28
The Journal of Physical Chemistry C (2014) 118, 25 13476
a=6.6162(4)Å b=7.6757(17)Å c=11.1002(13)Å
α=87.399(17)° β=104.322(7)° γ=96.289(9)°
Rubrene
C42H28
The Journal of Physical Chemistry C (2014) 118, 25 13476
a=14.2395(16)Å b=6.7738(13)Å c=11.2810(10)Å
α=81.264(14)° β=100.378(10)° γ=101.773(10)°
C8H15N2,PF6
C8H15N2,PF6
Chemical Science (2013) 4, 3 1270
a=8.8215(8)Å b=9.0796(9)Å c=9.0381(8)Å
α=96.671(7)° β=114.768(6)° γ=103.071(7)°
C8H15N2,PF6
C8H15N2,PF6
Chemical Science (2013) 4, 3 1270
a=9.4924(5)Å b=9.8406(5)Å c=26.8817(13)Å
α=90.00° β=90.00° γ=90.00°
C8H15N2,PF6
C8H15N2,PF6
Chemical Science (2013) 4, 3 1270
a=9.3869(8)Å b=9.5879(8)Å c=14.4964(12)Å
α=98.492(5)° β=98.354(6)° γ=101.089(6)°
C8H15N2,PF6
C8H15N2,PF6
Chemical Science (2013) 4, 3 1270
a=9.5818(13)Å b=9.5826(9)Å c=14.5801(10)Å
α=99.219(10)° β=99.252(6)° γ=99.667(10)°
Paracetamol monomethanolate
C9H13N1O3
Chemical Communications (Cambridge, United Kingdom) (2003) 24 3004-3005
a=7.630(2)Å b=17.209(3)Å c=7.3710(11)Å
α=90° β=115.52(3)° γ=90°
C17H17FN3O3,5(H2O),NA
C17H17FN3O3,5(H2O),NA
CrystEngComm (2009) 11, 7 1396
a=9.624(3)Å b=9.493(3)Å c=11.471(4)Å
α=89.643(6)° β=103.304(6)° γ=88.861(6)°
Ciprofloxacin
C17H18FN3O3
CrystEngComm (2009) 11, 7 1396
a=7.9606(2)Å b=8.5798(2)Å c=10.7739(3)Å
α=87.868(3)° β=85.153(2)° γ=88.212(1)°
2(C17H17FN3O3),10(H2O),2(Na)
2(C17H17FN3O3),10(H2O),2(Na)
CrystEngComm (2009) 11, 7 1396
a=11.065(10)Å b=13.155(12)Å c=13.879(12)Å
α=90.983(14)° β=98.941(14)° γ=93.181(14)°
C17H17.50F1N3O3,Na0.50,5(H2O)
C17H17.50F1N3O3,Na0.50,5(H2O)
CrystEngComm (2009) 11, 7 1396
a=9.452(3)Å b=9.591(4)Å c=11.233(6)Å
α=85.67(2)° β=99.62(2)° γ=93.74(2)°
C17H17FN3O3,5(H2O),NA
C17H17FN3O3,5(H2O),NA
CrystEngComm (2009) 11, 7 1396
a=9.547(7)Å b=9.870(7)Å c=11.109(12)Å
α=88.79(4)° β=101.42(4)° γ=90.25(2)°
C17H17.50F1N3O3,Na0.50,5(H2O)
C17H17.50F1N3O3,Na0.50,5(H2O)
CrystEngComm (2009) 11, 7 1396
a=9.391(8)Å b=9.570(8)Å c=11.095(9)Å
α=85.247(14)° β=99.498(13)° γ=93.272(14)°
C6H10N2O2
C6H10N2O2
CrystEngComm (2005) 7, 29 179
a=6.7254(2)Å b=13.2572(4)Å c=8.0529(2)Å
α=90° β=98.603(2)° γ=90°
C6H10N2O2,H2O
C6H10N2O2,H2O
CrystEngComm (2005) 7, 29 179
a=6.9376(2)Å b=7.4450(2)Å c=9.1267(2)Å
α=97.732(2)° β=103.958(2)° γ=115.766(2)°
C6H10N2O2
C6H10N2O2
CrystEngComm (2005) 7, 29 179
a=8.9537(11)Å b=5.4541(6)Å c=13.610(4)Å
α=90° β=104.93(2)° γ=90°
O-methyl-2-aminoisobutyric acid hydrochloride
C5H12NO2,Cl
Physical Chemistry Chemical Physics (2009) 11, 15 2601-2609
a=8.553(2)Å b=8.713(3)Å c=22.141(2)Å
α=90° β=90° γ=90°
O-methyl-2-aminoisobutyric acid hydrochloride
C5H12NO2,Cl
Physical Chemistry Chemical Physics (2009) 11, 15 2601-2609
a=8.5862(1)Å b=8.7421(1)Å c=22.2501(2)Å
α=90° β=90° γ=90°
O-methyl-2-aminoisobutyric acid hydrochloride
C5H12NO2,Cl
Physical Chemistry Chemical Physics (2009) 11, 15 2601-2609
a=8.5889(1)Å b=8.7603(1)Å c=22.2425(3)Å
α=90° β=90° γ=90°
O-methyl-2-aminoisobutyric acid hydrochloride
C5H12NO2,Cl
Physical Chemistry Chemical Physics (2009) 11, 15 2601-2609
a=8.5921(1)Å b=8.7611(1)Å c=22.2484(3)Å
α=90° β=90° γ=90°
O-methyl-2-aminoisobutyric acid hydrochloride
C5H12NO2,Cl
Physical Chemistry Chemical Physics (2009) 11, 15 2601-2609
a=8.6018(1)Å b=8.7828(1)Å c=22.2584(3)Å
α=90° β=90° γ=90°
Cytenamide form II
C16H13N1O1
CrystEngComm (2008) 10, 7 811
a=5.8100(2)Å b=19.6315(5)Å c=21.7087(6)Å
α=85.918(2)° β=86.164(2)° γ=84.482(2)°
Cytenamide form I
C16H13N1O1
CrystEngComm (2008) 10, 7 811
a=33.9078(10)Å b=33.9078(10)Å c=5.6754(2)Å
α=90° β=90° γ=120°
C15H12N2O1,0.1(C4H8O1)
C15H12N2O1,0.1(C4H8O1)
CrystEngComm (2007) 9, 9 728
a=35.243(5)Å b=35.243(5)Å c=5.1853(10)Å
α=90° β=90° γ=120°
C46H88Br4Mn8O24,2(C2H3N)
C46H88Br4Mn8O24,2(C2H3N)
Dalton transactions (Cambridge, England : 2003) (2006) 2 351-356
a=11.4048(2)Å b=12.8147(3)Å c=14.1353(3)Å
α=108.2590(10)° β=97.2100(10)° γ=110.7390(10)°
9,10-Diphenylanthracene 1,1,2,2-tetrachloroethane solvate
C26H18,2(C2H2Cl4)
CrystEngComm (2016) 18, 12 2173
a=8.7874(3)Å b=12.0308(7)Å c=13.8215(8)Å
α=90° β=104.964(3)° γ=90°
9,10-Diphenylanthracene
C26H18
CrystEngComm (2016) 18, 12 2173
a=10.041(2)Å b=13.150(2)Å c=11.378(2)Å
α=90° β=88.483(17)° γ=90°
9,10-Diphenylanthracene
C26H18
CrystEngComm (2016) 18, 12 2173
a=10.4702(9)Å b=13.3923(10)Å c=12.0158(11)Å
α=90° β=89.931(8)° γ=90°
DKH13A
C68H100N8O8Cu2.C2.5H5Cl5
Dalton transactions (Cambridge, England : 2003) (2010) 39, 7 1763-1770
a=14.0562(7)Å b=23.6030(12)Å c=12.4451(6)Å
α=90.00° β=106.9300(10)° γ=90.00°
C17H26N2O2
C17H26N2O2
Dalton transactions (Cambridge, England : 2003) (2010) 39, 7 1763-1770
a=20.1661(7)Å b=8.5773(3)Å c=20.6403(7)Å
α=90° β=114.661(2)° γ=90°
C34H52CuN4O4,2(BF4)
C34H52CuN4O4,2(BF4)
Dalton transactions (Cambridge, England : 2003) (2010) 39, 7 1763-1770
a=8.4253(3)Å b=10.7811(4)Å c=11.2498(4)Å
α=84.524(3)° β=77.179(2)° γ=69.818(2)°
C34H52Br4Cu2N4O4,1.75(CH3OH)
C34H52Br4Cu2N4O4,1.75(CH3OH)
Dalton transactions (Cambridge, England : 2003) (2010) 39, 7 1763-1770
a=16.8492(5)Å b=24.7009(8)Å c=10.5521(3)Å
α=90.00° β=90.00° γ=90.00°
C38H52Cu1F6N4O8
C38H52Cu1F6N4O8
Dalton transactions (Cambridge, England : 2003) (2010) 39, 7 1763-1770
a=11.5737(9)Å b=14.2590(11)Å c=12.8374(10)Å
α=90° β=108.688(3)° γ=90°
Paracetamol monomethanolate
C9H13N1O3
Chemical Communications (Cambridge, United Kingdom) (2003) 24 3004-3005
a=7.630(2)Å b=17.209(3)Å c=7.3710(11)Å
α=90° β=115.52(3)° γ=90°
Α-cyclodextrin hexahydrate
C36H60O30,6(H2O)
CrystEngComm (2012) 14, 24 8664
a=14.8815(4)Å b=33.7011(10)Å c=9.4872(2)Å
α=90.00° β=90.00° γ=90.00°
Α-cyclodextrin 6.8-hydrate
C36H60O30,6.8(H2O)
CrystEngComm (2012) 14, 24 8664
a=14.657(5)Å b=34.253(14)Å c=9.217(4)Å
α=90.00° β=90.00° γ=90.00°
C9H17NO2,7(H2O)
C9H17NO2,7(H2O)
CrystEngComm (2010) 12, 8 2354
a=6.7906(12)Å b=7.3159(4)Å c=15.8428(14)Å
α=86.297(6)° β=78.924(11)° γ=72.713(6)°
Cyanocobalamin hydrate
C63H88CoN14O14P,23.5H2O
CrystEngComm (2010) 12, 9 2541
a=15.8260(9)Å b=22.4438(13)Å c=25.4429(16)Å
α=90.00° β=90.00° γ=90.00°
Cyanocobalamin hydrate
C63H88CoN14O14P,22H2O
CrystEngComm (2010) 12, 9 2541
a=15.9455(4)Å b=21.0511(5)Å c=23.8739(8)Å
α=90.00° β=90.00° γ=90.00°
C8H15N2,PF6
C8H15N2,PF6
Chemical Science (2013) 4, 3 1270
a=9.3855(3)Å b=9.7769(3)Å c=26.7170(7)Å
α=90.00° β=90.00° γ=90.00°
C10H8
C10H8
Acta Crystallographica Section B (2018) 74, 5
a=7.7154(2)Å b=5.9019(1)Å c=7.6969(2)Å
α=90° β=100.411(2)° γ=90°
Chlorothiazide
C7H6Cl1N3O4S2
Acta Crystallographica Section B (2008) 64, 1 101-107
a=4.8499(3)Å b=6.3694(4)Å c=8.9106(6)Å
α=74.4010(10)° β=83.8650(10)° γ=80.5240(10)°
Hydrochlorothiazide form II
C7H8Cl1N3O4S2
Acta Crystallographica Section B (2008) 64, 1 101-107
a=9.4855(3)Å b=8.3325(2)Å c=15.1201(4)Å
α=90° β=113.240(3)° γ=90°
Β-cyclodextrin DMF 12.5 hydrate
C42H70O35,C3H7N1O1,12.5(H2O)
Acta Crystallographica Section B (2014) 70, 3 586-594
a=15.500(3)Å b=9.794(2)Å c=21.689(5)Å
α=90° β=90.138(3)° γ=90°
1-cyclopropyl-6-fiuoro-4-oxo-7-(1-piperazinyl)- 1,4-dihydroquinoline-3-carboxylic acid) 1.4hydrate hydrochloride
C17H19FN3O3,1.4(H2O),Cl
Journal of Applied Crystallography (2009) 42, 6 1110-1121
a=12.872(1)Å b=19.576(1)Å c=6.948(1)Å
α=90.0(0)° β=90.55(5)° γ=90.0(0)°
1-cyclopropyl-6-fiuoro-4-oxo-7-(1-piperazinyl)- 1,4-dihydroquinoline-3-carboxylic acid) hexahydrate
C17H18FN3O3,6(H2O)
Journal of Applied Crystallography (2009) 42, 6 1110-1121
a=9.5070(1)Å b=9.9649(1)Å c=11.0233(1)Å
α=94.182(1)° β=100.118(1)° γ=91.432(1)°
C7H11NO4,H2O
C7H11NO4,H2O
Acta Crystallographica Section A (2014) 70, 4 309-316
a=9.854(3)Å b=9.249(3)Å c=10.144(2)Å
α=90° β=90° γ=90°
C7H11NO4,H2O
C7H11NO4,H2O
Acta Crystallographica Section A (2014) 70, 4 309-316
a=9.853(4)Å b=9.251(5)Å c=10.145(2)Å
α=90° β=90° γ=90°
C7H11NO4,H2O
C7H11NO4,H2O
Acta Crystallographica Section A (2014) 70, 4 309-316
a=9.866(7)Å b=9.250(7)Å c=10.149(6)Å
α=90° β=90° γ=90°
C7H11NO4,H2O
C7H11NO4,H2O
Acta Crystallographica Section A (2014) 70, 4 309-316
a=9.9748(2)Å b=9.2492(2)Å c=10.2103(2)Å
α=90° β=90° γ=90°
C7H11NO4,H2O
C7H11NO4,H2O
Acta Crystallographica Section A (2014) 70, 4 309-316
a=9.9408(2)Å b=9.2479(2)Å c=10.1875(2)Å
α=90° β=90° γ=90°
C7H11NO4,H2O
C7H11NO4,H2O
Acta Crystallographica Section A (2014) 70, 4 309-316
a=9.9026(2)Å b=9.2485(2)Å c=10.1662(2)Å
α=90° β=90° γ=90°
L-hydroxyproline monohydrate
C7H11N1O4,H2O
Acta Crystallographica Section A (2014) 70, 4 309-316
a=9.854(3)Å b=9.249(3)Å c=10.144(2)Å
α=90° β=90° γ=90°
L-hydroxyproline monohydrate
C7H11N1O4,H2O
Acta Crystallographica Section A (2014) 70, 4 309-316
a=9.9748(2)Å b=9.2492(2)Å c=10.2103(2)Å
α=90° β=90° γ=90°
L-hydroxyproline monohydrate
C7H11N1O4,H2O
Acta Crystallographica Section A (2014) 70, 4 309-316
a=10.0123(2)Å b=9.2556(2)Å c=10.2441(2)Å
α=90° β=90° γ=90°
2(C10H9N1O2),C6H6O2
2(C10H9N1O2),C6H6O2
Acta Crystallographica Section E (2007) 63, 6 o2891-o2891
a=7.8841(19)Å b=8.480(2)Å c=9.887(3)Å
α=95.72(2)° β=109.85(3)° γ=113.50(2)°
Triphenylphosphine oxide--hydroquinone (1/1)
C18H15OP,C6H6O2
Acta Crystallographica Section E (2008) 64, 2 o367-o367
a=8.927(4)Å b=9.3576(10)Å c=14.459(4)Å
α=71.157(7)° β=73.826(6)° γ=62.83(2)°
Ciprofloxacin--2,2-difluoroethanol (2/3)
2(C17H18FN3O3),3(C2H4F2O)
Acta Crystallographica Section C (2011) 67, 3 o120-o124
a=10.9848(4)Å b=13.9800(4)Å c=13.9802(4)Å
α=105.6488(18)° β=90.352(2)° γ=93.364(2)°
Ciprofloxacin--water (3/14.5)
3(C17H18FN3O3),14.5(H2O)
Acta Crystallographica Section C (2011) 67, 3 o120-o124
a=13.8760(12)Å b=15.8760(13)Å c=16.528(2)Å
α=115.755(7)° β=103.610(7)° γ=102.325(5)°
Bendroflumethiazide acetone solvate
C15H14F3N3O4S2,C3H6O
Acta Crystallographica Section C (2007) 63, 11 o659-o663
a=8.192(2)Å b=9.525(2)Å c=14.101(2)Å
α=99.538(17)° β=100.171(17)° γ=100.42(2)°
Bendroflumethiazide N,N-dimethylformamide solvate
C15H14F3N3O4S2,C3H7NO
Acta Crystallographica Section C (2007) 63, 11 o659-o663
a=8.2527(3)Å b=17.8431(7)Å c=14.9012(5)Å
α=90° β=103.752(4)° γ=90°
(+)-6-aminopenicillanic acid
C8H12N2O3S
Acta Crystallographica Section C (2013) 69, 11 1238-1242
a=6.1954(4)Å b=10.4543(7)Å c=14.7654(9)Å
α=90° β=90° γ=90°
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline- 3-carboxylate hexahydrate
C17H18FN3O3,6(H2O)
Acta Crystallographica Section E (2008) 64, 12 o2354-o2355
a=9.5079(3)Å b=9.9437(3)Å c=11.0391(3)Å
α=94.227(2)° β=100.206(2)° γ=91.327(2)°
H2O9S2Ti,K
H2O9S2Ti,K
Chemistry of Materials (2008) 20, 1 8
a=7.6492(3)Å b=5.2580(2)Å c=9.0485(3)Å
α=90° β=101.742(2)° γ=90°
C14H27N2,Cl,0.5(H2O)
C14H27N2,Cl,0.5(H2O)
Crystal Growth & Design (2015) 15, 8 3875
a=7.3494(5)Å b=8.4551(5)Å c=42.735(7)Å
α=83.125(9)° β=89.000(9)° γ=69.871(4)°
C14H27N2,Cl,(H2O)
C14H27N2,Cl,(H2O)
Crystal Growth & Design (2015) 15, 8 3875
a=5.3387(19)Å b=7.7592(12)Å c=20.428(5)Å
α=82.056(17)° β=87.16(2)° γ=79.09(2)°
C14H27N2,Cl,(H2O)
C14H27N2,Cl,(H2O)
Crystal Growth & Design (2015) 15, 8 3875
a=5.3607(2)Å b=7.7232(2)Å c=20.4674(6)Å
α=82.1449(12)° β=87.2216(12)° γ=78.9156(12)°
C14H27N2,Cl,0.95(H2O)
C14H27N2,Cl,0.95(H2O)
Crystal Growth & Design (2015) 15, 8 3875
a=7.2807(2)Å b=8.4710(2)Å c=43.0059(11)Å
α=85.0460(13)° β=89.8188(14)° γ=70.9453(13)°
C14H27N2,Cl,3(H2O)
C14H27N2,Cl,3(H2O)
Crystal Growth & Design (2015) 15, 8 3875
a=5.3513(5)Å b=7.2152(8)Å c=22.706(5)Å
α=83.711(14)° β=89.209(13)° γ=82.429(7)°
C14H27N2,Cl,0.97(H2O)
C14H27N2,Cl,0.97(H2O)
Crystal Growth & Design (2015) 15, 8 3875
a=7.344(6)Å b=8.508(7)Å c=43.39(4)Å
α=84.77(5)° β=89.32(5)° γ=70.73(5)°
C14H27N2,Cl,0.47(H2O)
C14H27N2,Cl,0.47(H2O)
Crystal Growth & Design (2015) 15, 8 3875
a=7.3264(18)Å b=8.371(2)Å c=42.879(16)Å
α=82.900(7)° β=89.106(11)° γ=69.909(8)°
C14H27N2,Cl,3(H2O)
C14H27N2,Cl,3(H2O)
Crystal Growth & Design (2015) 15, 8 3875
a=5.2844(5)Å b=7.0547(4)Å c=22.364(2)Å
α=83.949(6)° β=88.487(7)° γ=83.478(6)°
[(CH4)3N][MnCl3]
[(CH4)3N][MnCl3]
Journal of the American Chemical Society (2006) 128, 28 9205-9210
a=9.1287(3)Å b=9.1287(3)Å c=6.4903(5)Å
α=90° β=90° γ=120°
[(CH4)3N][MnCl3]
[(CH4)3N][MnCl3]
Journal of the American Chemical Society (2006) 128, 28 9205-9210
a=9.0893(4)Å b=9.0893(4)Å c=6.4724(7)Å
α=90° β=90° γ=120°
[(CH4)3N][MnCl3]
[(CH4)3N][MnCl3]
Journal of the American Chemical Society (2006) 128, 28 9205-9210
a=8.9326(2)Å b=8.9326(2)Å c=6.4010(4)Å
α=90° β=90° γ=120°
[(CH4)3N][MnCl3]
[(CH4)3N][MnCl3]
Journal of the American Chemical Society (2006) 128, 28 9205-9210
a=8.8728(8)Å b=8.8728(8)Å c=6.3620(14)Å
α=90° β=90° γ=120°
[(CH4)3N][MnCl3]
[(CH4)3N][MnCl3]
Journal of the American Chemical Society (2006) 128, 28 9205-9210
a=9.0215(6)Å b=9.0215(6)Å c=6.4395(10)Å
α=90° β=90° γ=120°
[(CH4)3N][MnCl3]
[(CH4)3N][MnCl3]
Journal of the American Chemical Society (2006) 128, 28 9205-9210
a=9.1880(13)Å b=9.1880(13)Å c=6.5230(13)Å
α=90° β=90° γ=120°
C6H10N2O2
C6H10N2O2
Crystal Growth & Design (2007) 7, 6 1115
a=6.321(2)Å b=6.5597(11)Å c=8.380(4)Å
α=79.82(3)° β=102.34(3)° γ=90.94(2)°
C6H10N2O2
C6H10N2O2
Crystal Growth & Design (2007) 7, 6 1115
a=6.442(2)Å b=6.3530(11)Å c=8.737(3)Å
α=81.43(3)° β=112.88(2)° γ=91.38(2)°
C6H10N2O2
C6H10N2O2
Crystal Growth & Design (2007) 7, 6 1115
a=6.3903(7)Å b=6.2932(11)Å c=8.6450(16)Å
α=81.106(12)° β=113.680(12)° γ=91.295(11)°
C6H10N2O2
C6H10N2O2
Crystal Growth & Design (2007) 7, 6 1115
a=6.169(2)Å b=6.1602(11)Å c=8.287(3)Å
α=80.41(3)° β=115.33(3)° γ=91.15(2)°
C6H10N2O2
C6H10N2O2
Crystal Growth & Design (2007) 7, 6 1115
a=6.263(2)Å b=6.2063(10)Å c=8.412(3)Å
α=80.77(3)° β=114.69(2)° γ=91.12(2)°
C6H10N2O2,2(H2O)
C6H10N2O2,2(H2O)
Crystal Growth & Design (2007) 7, 6 1115
a=6.217(2)Å b=7.0356(9)Å c=10.0593(13)Å
α=84.711(12)° β=76.83(2)° γ=75.77(2)°
C7H11NO4,H2O
C7H11NO4,H2O
Acta Crystallographica Section A (2014) 70, 4 309-316
a=10.0123(2)Å b=9.2556(2)Å c=10.2441(2)Å
α=90° β=90° γ=90°
L-hydroxyproline monohydrate
C7H11N1O4,H2O
Acta Crystallographica Section A (2014) 70, 4 309-316
a=9.9408(2)Å b=9.2479(2)Å c=10.1875(2)Å
α=90° β=90° γ=90°